Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(66.7%)
Phase 2
3(33.3%)
9Total
Phase 1(6)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT05462353Phase 2Active Not Recruiting

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH

Role: lead

NCT05118516Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects

Role: lead

NCT05118360Phase 2Withdrawn

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

Role: lead

NCT05190523Phase 2Completed

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Role: lead

NCT04845646Phase 1Completed

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

Role: lead

NCT05464628Phase 1Completed

Drug Interaction Study of ASC42 With Atorvastatin

Role: lead

NCT04692025Phase 1Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers

Role: lead

NCT04686994Phase 1Completed

Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

Role: lead

NCT04679129Phase 1Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects

Role: lead

All 9 trials loaded